Clinical trial
Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset…
NCT00232596 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00232596 |
|---|---|
| Title | Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures |
| Acronym | RESTORE1 |
| Lead sponsor | GlaxoSmithKline, Industry |
| Collaborators | Bausch Health Americas, Inc. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Seizures |
| Intervention type | Drug |
| Interventions | Retigabine, Placebo |
| Enrollment | 306 |
| Start date | Sep 1, 2005 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Oct 4, 2005 |
| Last update posted | Dec 8, 2016 |
| Countries | Argentina, Brazil, Canada, Mexico, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: